JP2009539403A5 - - Google Patents

Download PDF

Info

Publication number
JP2009539403A5
JP2009539403A5 JP2009515413A JP2009515413A JP2009539403A5 JP 2009539403 A5 JP2009539403 A5 JP 2009539403A5 JP 2009515413 A JP2009515413 A JP 2009515413A JP 2009515413 A JP2009515413 A JP 2009515413A JP 2009539403 A5 JP2009539403 A5 JP 2009539403A5
Authority
JP
Japan
Prior art keywords
antibody
ligand binding
binding region
region comprises
antibody according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009515413A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009539403A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/012837 external-priority patent/WO2007145840A2/en
Publication of JP2009539403A publication Critical patent/JP2009539403A/ja
Publication of JP2009539403A5 publication Critical patent/JP2009539403A5/ja
Pending legal-status Critical Current

Links

JP2009515413A 2006-06-13 2007-05-31 癌を診断および処置するための組成物および方法 Pending JP2009539403A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81295506P 2006-06-13 2006-06-13
US87866107P 2007-01-05 2007-01-05
US87933607P 2007-01-09 2007-01-09
PCT/US2007/012837 WO2007145840A2 (en) 2006-06-13 2007-05-31 Compositions and methods for diagnosing and treating cancer

Publications (2)

Publication Number Publication Date
JP2009539403A JP2009539403A (ja) 2009-11-19
JP2009539403A5 true JP2009539403A5 (enExample) 2010-07-15

Family

ID=38832293

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009515413A Pending JP2009539403A (ja) 2006-06-13 2007-05-31 癌を診断および処置するための組成物および方法

Country Status (7)

Country Link
US (5) US7919092B2 (enExample)
EP (1) EP2032166B1 (enExample)
JP (1) JP2009539403A (enExample)
CA (1) CA2655362A1 (enExample)
ES (1) ES2413087T3 (enExample)
PL (1) PL2032166T3 (enExample)
WO (1) WO2007145840A2 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1718767B1 (en) * 2004-02-03 2012-04-11 The Regents Of The University Of Michigan Compositions for treating breast and pancreatic cancer
CA2655362A1 (en) 2006-06-13 2007-12-21 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
HUE028379T2 (en) * 2006-09-29 2016-12-28 Oncomed Pharm Inc Preparations and procedures for the diagnosis and treatment of cancer
TWI419904B (zh) 2006-12-18 2013-12-21 Genentech Inc 拮抗劑抗-notch3抗體及其用於預防及治療notch3相關疾病之用途
AU2008209482B2 (en) 2007-01-24 2014-05-01 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
HRP20151261T1 (hr) 2007-07-02 2016-01-01 Oncomed Pharmaceuticals, Inc. Sastavi i postupci za lijeäśenje i dijagnosticiranje raka
AU2009235467A1 (en) * 2008-04-07 2009-10-15 Ablynx Nv Single variable domains against the Notch pathways
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
NZ590127A (en) * 2008-07-08 2012-11-30 Oncomed Pharm Inc Notch1 receptor binding agents and methods of use thereof
US8834875B2 (en) 2010-01-13 2014-09-16 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
PE20120080A1 (es) * 2008-10-01 2012-02-17 Genentech Inc Anticuerpos anti-notch2 y metodos de uso
US20110286916A1 (en) * 2008-11-20 2011-11-24 Jose Miguel Aste-Amezaga Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
WO2010146550A1 (en) 2009-06-18 2010-12-23 Pfizer Inc. Anti notch-1 antibodies
WO2011009064A1 (en) * 2009-07-17 2011-01-20 The J. David Gladstone Institutes Methods of controlling cell proliferation
ES2895226T3 (es) 2009-10-16 2022-02-18 Mereo Biopharma 5 Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensivos
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt拮抗劑及治療和篩選方法
WO2011140295A2 (en) * 2010-05-06 2011-11-10 President And Fellows Of Harvard College Modulators of notch receptor signaling and methods of use thereof
WO2012003472A1 (en) * 2010-07-02 2012-01-05 Aveo Pharmaceuticals, Inc. Anti-notch1 antibodies
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
WO2012080926A2 (en) 2010-12-15 2012-06-21 Wyeth Llc Anti-notch1 antibodies
DK2668210T3 (da) 2011-01-26 2020-08-24 Celldex Therapeutics Inc Anti-kit antistoffer og anvendelser deraf
CN103501823B (zh) 2011-02-17 2018-05-04 杜兰教育基金委员会 多组分组合物以及它们的用途
RU2477723C2 (ru) 2011-06-16 2013-03-20 Общество С Ограниченной Ответственностью "Фьюжн Фарма" Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
BR112014000765A2 (pt) 2011-07-15 2017-06-13 Oncomed Pharm Inc agentes de ligação a rspo e seus usos
PT2758073T (pt) 2011-09-23 2019-02-01 Oncomed Pharm Inc Agentes de ligação a vegf/dll4 e utilizações dos mesmos
US9663573B2 (en) * 2011-10-05 2017-05-30 Genentech, Inc. Methods of treating liver conditions using Notch2 antagonists
WO2013173542A1 (en) * 2012-05-16 2013-11-21 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with notch2/3 antibodies
MX2015000565A (es) 2012-07-13 2015-04-10 Oncomed Pharm Inc Agentes de union de proteina de r-espondina humana (rspo3) y usos de los mismos.
RU2681730C2 (ru) * 2012-07-25 2019-03-12 Селлдекс Терапьютикс Инк. Антитела против kit и их применения
GB2505489A (en) 2012-08-31 2014-03-05 Sony Corp A mobile communications device for use in a virtual narrowband carrier within a wideband carrier of a mobile communications system
EP2914961A4 (en) 2012-10-31 2016-04-20 Oncomed Pharm Inc METHODS AND MONITORING A TREATMENT BY AN ANTAGONIST OF DLL4
EP2970468B1 (en) 2013-03-13 2021-07-07 Novartis AG Notch2 binding molecules for treating respiratory diseases
KR101556011B1 (ko) 2013-07-10 2015-10-01 한국생명공학연구원 Jagged 1에 대한 인간 단일클론항체
EP3017641B1 (en) * 2013-11-12 2019-10-02 Huawei Technologies Co., Ltd. System and method for high efficiency wireless local area network communications
JP6389262B2 (ja) 2014-01-15 2018-09-12 華為技術有限公司Huawei Technologies Co.,Ltd. アップリンクofdma伝送のためのシステムおよび方法
CN113975386A (zh) 2014-05-23 2022-01-28 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
MX2017000363A (es) 2014-07-11 2017-04-27 Genentech Inc Inhibicion de la via de notch.
US10329323B2 (en) * 2014-07-25 2019-06-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Method for purifying antibodies using PBS
AU2015338974B2 (en) 2014-10-31 2021-08-26 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
US10894051B2 (en) * 2017-05-31 2021-01-19 City University Of Hong Kong Method of treating metastatic cancer in a subject
CN113227128B (zh) * 2018-07-20 2024-06-21 香港理工大学 针对抑制jag1-notch1信号通路的肽
EP3863550A4 (en) * 2018-10-12 2022-09-28 Immunolight, Llc. METHODS, DEVICES AND COMPOSITIONS FOR MEASUREMENT AND INDUCTION OF CELL-TO-CELL COMMUNICATION AND THERAPEUTIC USES THEREOF
EP3873612A2 (en) * 2018-11-01 2021-09-08 Merck Patent GmbH Methods of administering anti-tim-3 antibodies
CN113621060B (zh) * 2020-05-07 2023-07-04 浙江瑞硕生物技术有限公司 一种opg抗体对及其应用
JP2024511277A (ja) 2021-02-19 2024-03-13 メビオン・メディカル・システムズ・インコーポレーテッド 粒子線治療システムのためのガントリー

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE122009000019I1 (de) 1991-04-25 2009-07-16 Chugai Seiyaku K K 5 1 Rekombinierte humane antikörper gegen den humanen interleukin-6 rezeptor
IE20030749A1 (en) * 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
IL101728A (en) 1991-05-03 2007-08-19 Univ Yale Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
US20050112121A1 (en) 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
DE4425115A1 (de) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
WO1996036361A1 (en) 1995-05-18 1996-11-21 The Regents Of The University Of Michigan Dna binding antibodies
CA2250394A1 (en) 1996-03-30 1997-10-09 Boehringer Mannheim Gmbh Method for the production of activated marked tumor-specific t cells and use thereof in treatment of tumors
JP2000512134A (ja) 1996-05-31 2000-09-19 ザ ナショナル アメリカン レッド クロス Jagged/Notchタンパク質および核酸に基づく治療および診断の方法および組成物
FR2751986B1 (fr) * 1996-08-01 1998-12-31 Inst Nat Sante Rech Med Gene implique dans le cadasil, methode de diagnostic et application therapeutique
CA2271248C (en) 1996-11-07 2009-08-11 Jonathan Robert Lamb Use of a notch ligand in immunotherapy
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6379925B1 (en) 1997-06-18 2002-04-30 The Trustees Of Columbia University In The City Of New York Angiogenic modulation by notch signal transduction
WO1998057621A1 (en) 1997-06-18 1998-12-23 The Trustees Of Columbia University In The City Ofnew York Angiogenic modulation by notch signal transduction
US6692919B1 (en) * 1997-07-23 2004-02-17 Yale University Activated forms of notch and methods based thereon
US6004528A (en) * 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
US7361336B1 (en) * 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
AU768269B2 (en) 1998-10-02 2003-12-04 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Apoptosis inducing agents and methods
US20030003572A1 (en) 1999-03-05 2003-01-02 David J. Anderson Isolation and enrichment of neural stem cells from uncultured tissue based on cell-surface marker expression
US20020010320A1 (en) 1999-04-05 2002-01-24 James W. Fett Chemeric and humanized antibodies to angiogenin
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US20030031670A1 (en) * 1999-11-08 2003-02-13 Jack R. Wands Diagnosis and treatment of malignant neoplasms
DE10031380A1 (de) 2000-06-28 2002-01-10 Merck Patent Gmbh Verfahren zur Übertragung von Alkyliden-Gruppen auf organischen Verbindungen
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US20080194022A1 (en) 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
AU2001288628A1 (en) 2000-08-31 2002-03-13 Loyola University Chicago Method and reagents for treatment of skin disorders by modulating the notch pathway
US6689744B2 (en) * 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
EP1322761A4 (en) 2000-10-02 2005-03-23 Korea Res Inst Of Bioscience HUMANIZED ANTIBODY AGAINST THE HEPATITE B VIRUS SURFACE ANTIGEN AND METHOD OF PREPARING THE SAME
ATE484522T1 (de) 2001-04-24 2010-10-15 Bayer Corp Menschliche antikörper gegen timp-1
US7356224B2 (en) * 2001-07-03 2008-04-08 Brown University Research Foundation Method and apparatus for detecting multiple optical wave lengths
EP1415342B1 (de) * 2001-07-30 2006-06-07 BISTEKOS, Michael-Georg Einrichtung zur kühlung von gehausen, raumen, bauteilen, medien u. dgl
WO2003042246A2 (en) 2001-11-14 2003-05-22 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
CA2469204A1 (en) 2001-12-07 2003-06-19 Regents Of The University Of Michigan Prospective identification and characterization of breast cancer stem cells
GB0201674D0 (en) 2002-01-25 2002-03-13 Lorantis Ltd Medical treatment
JP2005530856A (ja) 2002-06-21 2005-10-13 ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン 膜関連腫瘍内皮マーカー
JP2006515747A (ja) * 2002-11-01 2006-06-08 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
WO2004052389A2 (en) * 2002-12-06 2004-06-24 Singapore General Hospital Pte Ltd. Nogo, caspr, f3 nb-3 useful in the treatment of injury and disease to the central nervous system
EP2060918A3 (en) 2003-04-01 2009-08-26 The Johns Hopkins University Breast endothelial cell expression patterns
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
GB0321805D0 (en) 2003-09-18 2003-10-15 Univ Wales Medicine Human tumour growth patterns
WO2005054434A2 (en) * 2003-11-26 2005-06-16 Health Research, Inc. Use of notch pathway interfering agents for treatment of plasma cell disorders
EP1718767B1 (en) 2004-02-03 2012-04-11 The Regents Of The University Of Michigan Compositions for treating breast and pancreatic cancer
WO2005090981A2 (en) 2004-03-24 2005-09-29 Technion Research & Development Foundation Ltd. Electrode
WO2005111072A2 (en) 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
US20070077245A1 (en) 2004-08-04 2007-04-05 The Brigham And Women's Hospital, Inc. NOTCH mutations leading to increased receptor signaling
GB0421838D0 (en) * 2004-09-30 2004-11-03 Congenia S R L Cancer markers
WO2006053063A2 (en) 2004-11-05 2006-05-18 The Regents Of The University Of California Notch-1 assay to detect neurodegenerative diseases
US20070265246A1 (en) * 2004-11-10 2007-11-15 Clevers Johannes C Treatment of an Intestinal Adenoma and/or Adenocarcinoma by Inhibition of Notch Pathway Activation
US10538742B2 (en) * 2004-11-12 2020-01-21 Cambridge Enterprise Limited Methods and means related to cancer stem cells
EP2083088A3 (en) 2005-04-07 2009-10-14 Novartis Vaccines and Diagnostics, Inc. Cancer-related genes
WO2007061988A2 (en) 2005-11-22 2007-05-31 University Of Vermont And State Agricultural College Methods for determining notch signaling and uses thereof
WO2007075915A2 (en) 2005-12-22 2007-07-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies against orthopoxviruses
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
WO2008057144A2 (en) 2006-05-15 2008-05-15 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human notch1 and 2 and isolated lnr domains from human notch1
CA2655362A1 (en) 2006-06-13 2007-12-21 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
HUE028379T2 (en) 2006-09-29 2016-12-28 Oncomed Pharm Inc Preparations and procedures for the diagnosis and treatment of cancer
CA2666672A1 (en) * 2006-10-19 2008-05-02 Genentech, Inc. Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
CA2666179A1 (en) 2006-10-19 2008-11-13 Genentech, Inc. Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
US7700113B2 (en) * 2006-10-19 2010-04-20 Maine Medical Research Institute, A Division Of Maine Medical Center Inhibiting breast cancer cell growth by administering an intracellular domain of NOTCH2
WO2008057114A1 (en) 2006-11-06 2008-05-15 Howard Shapiro Management of teaching processes for individualized instruction in a multi-student environment
TWI419904B (zh) * 2006-12-18 2013-12-21 Genentech Inc 拮抗劑抗-notch3抗體及其用於預防及治療notch3相關疾病之用途
AU2008209482B2 (en) 2007-01-24 2014-05-01 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US20090208491A1 (en) 2007-02-14 2009-08-20 Austin Gurney Compositions and Methods for Diagnosing and Treating Cancer
JP2010520280A (ja) 2007-03-05 2010-06-10 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム NotchまたはNumb特異的免疫療法との相乗効果を有する、癌細胞の再生のネガティブな遺伝的制御
WO2008109075A2 (en) 2007-03-05 2008-09-12 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
CN106432496B (zh) 2007-07-16 2020-02-07 健泰科生物技术公司 抗cd79b抗体和免疫偶联物及使用方法
BRPI0815291A2 (pt) 2007-08-23 2015-02-03 Univ Columbia "proteina de fusão, metodo de tratamento de pacientes que possuem um tumor, método de inibição da angiogênese em pacientes, método de tratamento de pacientes que possuem câncer do ovário, método de tratamento de pacientes que possuem um distúrbio metábolico, uso de proteína de fusão, método de inibição de linfoangiogênese patológica em pacientes, método de inibição da metástase de tumores em pacientes, método de inibição do crescimento de tumores secundários em pacientes, métodos de inibição da cooptação de vasos sanguineos por um tumor em pacientes, método de tratamento de cancer em pacientes e método de tratamento da retinopatia proliferativa vascular"
CA2697106A1 (en) 2007-08-28 2009-03-12 Donald Bergstrom Expression profiles of biomarker genes in notch mediated cancers
WO2009035522A1 (en) 2007-09-14 2009-03-19 Albert Einstein College Of Medicine Of Yeshiva University Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
US7807630B2 (en) 2007-09-14 2010-10-05 Vanderbilt University Targeting of Notch3 receptor function for cancer therapy
US20120082659A1 (en) 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
US8119366B2 (en) 2007-10-05 2012-02-21 Trojan Technologies, Ltd. Antennapedia-dominant negative mastermind-like construct
AU2009235467A1 (en) 2008-04-07 2009-10-15 Ablynx Nv Single variable domains against the Notch pathways
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
US8834875B2 (en) 2010-01-13 2014-09-16 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
NZ590127A (en) 2008-07-08 2012-11-30 Oncomed Pharm Inc Notch1 receptor binding agents and methods of use thereof
PE20120080A1 (es) 2008-10-01 2012-02-17 Genentech Inc Anticuerpos anti-notch2 y metodos de uso
JP2012520325A (ja) 2009-03-13 2012-09-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア プレバイオティックオリゴ糖
RU2012117619A (ru) 2009-09-30 2013-11-10 Дженентек, Инк. ЛЕЧЕНИЕ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ, УСТОЙЧИВЫХ К ДЕЙСТВИЮ АНТАГОНИСТА Notch1, С ПОМОЩЬЮ АНТАГОНИСТА Notch3
DE102009047243A1 (de) 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien
WO2011100566A2 (en) 2010-02-12 2011-08-18 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
JP5450221B2 (ja) 2010-04-14 2014-03-26 株式会社神戸製鋼所 高電流密度ガスシールドアーク溶接方法
KR20200044999A (ko) 2010-05-04 2020-04-29 파이브 프라임 테라퓨틱스, 인크. Csf1r에 결합하는 항체들
WO2012003472A1 (en) 2010-07-02 2012-01-05 Aveo Pharmaceuticals, Inc. Anti-notch1 antibodies
WO2012080926A2 (en) 2010-12-15 2012-06-21 Wyeth Llc Anti-notch1 antibodies
PL2683406T3 (pl) 2011-03-11 2019-11-29 Beth Israel Deaconess Medical Ct Inc Przeciwciała anty-cd40 i ich zastosowania
CN104105702B (zh) 2011-11-16 2016-11-23 昂考梅德药品有限公司 人notch受体突变及其应用
WO2013173542A1 (en) 2012-05-16 2013-11-21 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with notch2/3 antibodies
WO2014039533A2 (en) 2012-09-04 2014-03-13 Eleison Pharmaceuticals, Llc Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
AU2013317886A1 (en) 2012-09-21 2015-04-09 Oncomed Pharmaceuticals, Inc. Methods of treating hematological malignancies with NOTCH1 antibodies
BR112015010436A2 (pt) * 2012-11-07 2017-08-22 Pfizer Anticorpos anti-notch3 e conjugados anticorpo-fármaco
WO2014151606A2 (en) 2013-03-15 2014-09-25 Oncomed Pharmaceuticals, Inc. Methods of treating pancreatic cancer
WO2015134627A1 (en) 2014-03-07 2015-09-11 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with notch1 antibodies
WO2015153997A2 (en) 2014-04-04 2015-10-08 Oncomed Pharmaceuticals, Inc. Notch3 antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2009539403A5 (enExample)
JP7270522B2 (ja) 増殖分化因子15(gdf-15)に対するモノクローナル抗体
JP2023098966A (ja) 成長分化因子15(gdf-15)に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用
KR102196450B1 (ko) Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
TW201705982A (zh) 抗體-藥物結合物之選擇的製造方法
JP2008508858A5 (enExample)
Pan et al. Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement
WO2020247873A1 (en) Antigen-binding protein constructs and uses thereof
CN115605513A (zh) 一种抗pd-l1和her2的双特异性抗体
Chu Targeting mesothelin in solid tumours: anti-mesothelin antibody and drug conjugates
EP4069372A1 (en) Anti-clec-1a antibodies and antigen-binding fragment thereof
CN117940459A (zh) 靶向egfr和her3的双特异性四价抗体
CN115916839A (zh) 抗pdl1×egfr的双特异性抗体
WO2022205021A1 (zh) 一种抗angptl3抗体或其抗原结合片段及其制备方法和用途
EP4028420A1 (en) Antigen-binding protein constructs and uses thereof
Yang et al. Fully human recombinant antibodies against EphA2 from a multi-tumor patient immune library suitable for tumor-targeted therapy
Yue et al. A bispecific antibody targeting HER2 and CLDN18. 2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function
WO2020247827A1 (en) Antigen-binding protein constructs and uses thereof
US12448454B2 (en) Humanized anti-CLEC-1A antibodies and antigen-binding fragments thereof
KR102259298B1 (ko) 암 줄기세포 세포막 단백질에 특이적인 항체 및 그 응용
AU2022254042A1 (en) Antigen-binding protein constructs and antibodies and uses thereof
WO2021067673A1 (en) Antigen-binding protein constructs and uses thereof
CN115698085A (zh) 一种抗pd-l1和egfr的四价双特异性抗体
JP2023523981A (ja) TGFβR2細胞外ドメイン短縮分子、TGFβR2細胞外ドメイン短縮分子と抗EGFR抗体との融合タンパク質、及び融合タンパク質の抗腫瘍使用
KR102185755B1 (ko) 암 줄기세포 특이적 세포막 단백체 및 항체 발굴 방법 및 그 응용